Erratum: Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. (Cancer., (2011) 117, (162-174), 10.1002/cncr.25581);Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis

Cancer

Volumn 117, Issue 1, 2011, Pages 162-174

  Pallini, Roberto ^a   Ricci Vitiani, Lucia ^b   Montano, Nicola ^a   Mollinari, Cristiana ^b,c   Biffoni, Mauro ^b   Cenci, Tonia ^a   Pierconti, Francesco ^a   Martini, Maurizio ^a   De Maria, Ruggero ^b   Larocca, Luigi Maria ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Superior Health Institute   (Italy)

^c CNR   (Italy)

Author keywords

cancer stem cells; CD133; glioblastoma; tumor recurrence

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN REGION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CELL POPULATION; CELL TRANSPORT; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOTOMY; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERPHASE; KARNOFSKY PERFORMANCE STATUS; MALE; MOUSE; NEURAL STEM CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TISSUE SPECIFICITY;

EID: 78650705036     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30147     Document Type: Erratum

References (35)

1. Stupp R, Mason WP, van den Bent MJ, et al. European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
2. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63: 5821-5828.
3. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004; 64: 7011-7021.
4. Singh SK, Hawkins C, Clarke ID, et al. Identification of brain tumor initiating cells. Nature. 2004; 432: 396-401.
5. Berger F, Gay E, Pelletier L, Tropel P, Wion D., Development of gliomas: potential role of asymmetrical cell division of neural stem cells. Lancet Oncol. 2004; 5: 511-514.
6. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) gliobalstoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67: 4010-4015.
7. Zheng X, Shen G, Yang X, Liu W., Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res. 2007; 67: 3691-3697.
8. Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008; 122: 761-768.
9. Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastoma. Lab Invest. 2008; 88: 808-815.
10. Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008; 14: 123-129.
11. Beier D, Wischhusen J, Dietmaier W, et al. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol. 2008; 18: 370-377.
12. Pallini R, Ricci-Vitiani L, Banna GL, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008; 14: 8205-8212.
13. Rebetz J, Tian D, Persson A, et al. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal differentiation potential in high-grade glioma [serial online]. PloS One. 2008; 3: e1936.
14. Zhang M, Song T, Yang L, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients [serial online]. J Exp Clin Cancer Res. 2008; 27: 85.
15. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma [serial online]. Mol Cancer. 2006; 5: 67.
16. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Diff. 2006; 13: 1238-1241.
17. Kang MK, Kang SK., Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 2007; 16: 837-847.
18. Shervington A, Lu C., Expression of multidrug resistance in normal and cancer stem cells. Cancer Invest. 2008; 26: 535-542.
19. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444: 756-760.
20. Aboody KS, Brown A, Rainov NG, et al. From the cover: neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000; 97: 12846-12851.
21. Dietrich J, Imitola J, Kesari S., Mechanisms of disease: the role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol. 2008; 5: 393-404.
22. El Maarouf A, Petridis AK, Rutishauser U., Use of polysialic acid in repair of the central nervous system. Proc Natl Acad Sci U S A. 2006, 103: 16989-16994.
23. Cavenee WK, Furnari FB, Nagane M, Huang HJS, Newcomb EW, Bigner DD., Diffusely infiltrating astrocytomas. In:, Kleihues P, Cavenee CW, eds. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumours. 2nd ed. Lyon, France: IARC Press; 2000: 10-21.
24. Falchetti ML, Pierconti F, Casalbore P, et al. Glioblastoma induces vascular endothelial cells to express telomerase in vitro. Cancer Res. 2003; 63: 3750-3754.
25. Ricci-Vitiani L, Pallini R, Larocca LM, et al. Mesenchymal differentiation of glioblastoma stem cells. Cell Death Diff. 2008; 15: 1491-1498.
26. James CD, Carlbom E, Dumanski JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 1988; 48: 5546-5551.
27. Roversi G, Pfundt R, Moroni RF, et al. Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene. 2006; 25: 1571-1583.
28. Paternoster SF, Brockman SR, McClure RF, Remstein ED, Kurtin PJ, Dewald GW., A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol. 2002, 160: 1967-1972.
29. Gorlia TS, Eisenhauer R, Mirimanoff EA, et al. European Organisation for Research and Treatment of Cancer (EORTC) Brain and Radiotherapy Groups, National Cancer Institute of Canada (NCIC) Clinical Trials Group: clinical prognostic factors affecting survival in patients with newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol. 2004; 22: 859s.Abstract 9599.
30. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006; 24: 2563-2569.
31. Timmermans F, Van Hauwermeiren F, De Smedt M, et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol. 2007; 27: 1572-1579.
32. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000; 95: 952-958.
33. Ribatti D., The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med. 2004; 8: 294-300.
34. Casalbore P, Budoni M, Ricci-Vitiani L, et al. Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1 [serial online]. PLoS One. 2009; 4: e4434.
35. Glass R, Synowitz M, Kronenberg G, et al. Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci. 2005; 25: 2637-2646.